Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

67 recruiting

Showing 120 of 120 trials

Recruiting
Phase 1Phase 2

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited114 enrolled10 locationsNCT06414460
Recruiting
Phase 2

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Non-small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd86 enrolled17 locationsNCT07164170
Recruiting
Phase 2Phase 3

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Breast Neoplasms
Bristol-Myers Squibb500 enrolled295 locationsNCT06926868
Recruiting
Phase 1Phase 2

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.178 enrolled3 locationsNCT07512583
Recruiting
Phase 1

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Advanced Solid Tumor
BeOne Medicines308 enrolled37 locationsNCT06233942
Recruiting
Phase 1

A Study of BG-C477 in Participants With Advanced Solid Tumors

Advanced Solid Tumors
BeOne Medicines310 enrolled52 locationsNCT06596473
Recruiting
Phase 1

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Breast CancerAdvanced Solid Tumor
BeOne Medicines86 enrolled27 locationsNCT07222267
Recruiting
Phase 1

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

Advanced Solid Tumor
BeOne Medicines105 enrolled21 locationsNCT07226349
Recruiting
Phase 1

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

Advanced Solid Tumor
BeOne Medicines525 enrolled87 locationsNCT06589596
Recruiting
Phase 3

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Extensive-stage Small-cell Lung Cancer
BioNTech SE621 enrolled202 locationsNCT06712355
Recruiting
Phase 1

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

Advanced Solid Tumor
BeOne Medicines153 enrolled26 locationsNCT06598800
Recruiting
Phase 3

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
BeOne Medicines351 enrolled93 locationsNCT07043400
Recruiting
Phase 1

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Advanced Solid TumorSolid Tumors
BeOne Medicines63 enrolled14 locationsNCT07181681
Recruiting
Phase 1Phase 2

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

Advanced Solid Tumor
Nanjing Leads Biolabs Co.,Ltd396 enrolled49 locationsNCT05170958
Recruiting
Early Phase 1

A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors

Advanced CancerCachexia
Jiangsu Nutai Biologics Co., Ltd28 enrolled1 locationNCT06736275
Recruiting
Phase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 2

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.60 enrolled1 locationNCT07329322
Recruiting
Phase 3

A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

Non-small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company300 enrolled2 locationsNCT06930794
Recruiting
Early Phase 1

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

HER2-Positive Advanced Solid Tumors
Shanghai Pharmaceuticals Holding Co., Ltd150 enrolled17 locationsNCT05245058
Recruiting
Phase 1Phase 2

A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.465 enrolled37 locationsNCT07367529